Compare Enveric Biosciences Inc (ENVB) vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF (VTIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF — how do they compare? Enveric Biosciences Inc trades at $1.48 (market cap $6.80M), while Vanguard Sht-Term Inflation-Protected Sec Idx ETF trades at $48.46 (market cap $73.20B). The key difference: Vanguard Sht-Term Inflation-Protected Sec Idx ETF is far larger — about 10764.7× Enveric Biosciences Inc's market cap, and Enveric Biosciences Inc is more actively traded (64,867 versus 2,511,360). Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Vanguard Sht-Term Inflation-Protected Sec Idx ETF for 91 Days on average.
| ENVB | VTIP | |
|---|---|---|
Market Cap | $6.80M | $73.20B |
Volume | 64,867 | 2,511,360 |
Sector | Health | — |
52-Week High | $10.80 | $50.46 |
52-Week Low | $1.27 | $48.38 |
Typical Hold Time | 14 Days | 91 Days |
Enterprise Value | -$1.49M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.48, down 1.0% today, with a bearish technical signal from moving averages but neutral oscillators. The company shows negative profitability with ROE at -235.48% and ROA at -193.53%, though it has beaten EPS expectations for four consecutive quarters. Recent developments include patent allowances for non-hallucinogenic therapeutics and positive preclinical data for EB-003.
While analyst consensus is 75% buy with no sell ratings, fundamental weaknesses in revenue generation and negative cash flow from operations pose significant risks. The stock's appeal hinges on clinical progress and regulatory milestones, making it suitable for risk-tolerant investors betting on biotech innovation amid high operational and financial volatility.
VTIP, the Vanguard Short-Term Inflation-Protected Securities ETF, trades at $48.46 with no change in the last session. The technical outlook is bearish based on moving averages, though oscillators signal bullish momentum with RSI levels in oversold territory. Recent news highlights its role as a hedge against inflation and rising rates, with institutional investors increasing positions. Key support is at $48, with resistance at $49.
The outlook for VTIP is supported by its design to mitigate inflation risk amid persistent price pressures, but it faces headwinds from Federal Reserve policy uncertainty. Investment appeal lies in its short-duration TIPS focus, reducing interest-rate sensitivity, while risks include potential inflation moderation and real yield volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Vanguard Sht-Term Inflation-Protected Sec Idx ETF
The index is a market-capitalization-weighted index that includes all inflation-protected public obligations issued by the US Treasury with remaining maturities of less than 5 years. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the securities that make up the index, holding each security in approximately the same proportion as its weighting in the index.
Read more on VTIP →
